AAA
ITOS

Affinity Asset Advisors’s iTeos Therapeutics ITOS Stock Holding History

Affinity Asset Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,000
Closed -$641K – 83
2021
Q2 		$641K Buy
+25,000
New +$596K 0.23% 63

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Affinity Asset Advisors's ITOS Position: Q3 2021 in Review

Affinity Asset Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2021, closing a stake of 25,000 shares — an estimated $641K sold.

Affinity Asset Advisors first reported a position in ITOS in Q2 2021 and held it in 1 quarter. The position peaked at $641K in Q2 2021. 77 funds tracked by Wall St. Rank hold ITOS as of Q3 2021.

  • Affinity Asset Advisors reported no remaining iTeos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 25,000 iTeos Therapeutics shares in Q3 2021, an estimated $641K.
  • Affinity Asset Advisors first reported a position in iTeos Therapeutics in Q2 2021 and held it in 1 quarter.
  • Affinity Asset Advisors's iTeos Therapeutics position peaked at $641K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2021.

Based on Affinity Asset Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.